Interventions for valvular disease and heart failure

Life expectancy of patients with a transcatheter aortic valve and the implications for long-term valve durability data collection

EuroIntervention 2023;18:996-998. DOI: 10.4244/EIJ-D-22-00493

Maarten Vanhaverbeke
Maarten Vanhaverbeke1, MD, PhD; Lars Sondergaard1, MD, DMSc; Ole De Backer1, MD, PhD
1. Heart Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Introduction Transcatheter aortic valve implantation (TAVI) has become a therapeutic standard for patients with symptomatic severe aortic stenosis (AS) across all surgical risk categories. In the European guidelines for the management of patients with valvular heart disease, TAVI received a class 1 recommendation for the treatment of patients with symptomatic severe AS aged ≥75 years, and the lower age limit was set as low as 65 years in the American guidelines12. Both the European and American guidelines emphasise the importance of balancing the life expectancy of the patient with the valve durability when considering a surgical or transcatheter bioprosthetic valve. However, robust ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Double chimney stenting without contrast during transcatheter aortic valve-in-valve implantation

Latest news